| Topic area | Key findings/statistics | Evidence type | Publication (authors, journal) | Year-month | Identifier | URL |
|---|---|---|---|---|---|---|
| Definition / phenotype | Swyer syndrome = 46,XY complete gonadal dysgenesis with female phenotype; typical presentation is primary amenorrhea, delayed/absent puberty, hypergonadotropic hypogonadism, streak gonads, and usually a small/hypoplastic uterus; incidence reported as ~1:80,000 in a case report (pqac-00000000, pqac-00000003) | Case report / review | Sandilya & Jha, *Journal of Rare Diseases* | 2023-09 | DOI: 10.1007/s44162-023-00016-9 | https://doi.org/10.1007/s44162-023-00016-9 |
| Definition / phenotype / genetics | Phenotypic female with 46,XY karyotype, primary amenorrhea, lack of secondary sexual characteristics, infantile uterus, streak gonads; genetics summarized as SRY mutation in 10–20% while most have normal SRY; other implicated genes include **DHH, NR5A1, DAX1** duplication, and gain-of-function **MAP3K1** variants (pqac-00000004) | Case report / review | Jawed et al., *Women’s Health* | 2023-01 | DOI: 10.1177/17455057231213270 | https://doi.org/10.1177/17455057231213270 |
| Tumor risk / management | Tumor risk rises with age: ~**5% by age 15** and **27.5% by age 30**; gonadectomy recommended for every diagnosed patient; prophylactic bilateral gonadectomy/salpingectomy emphasized (pqac-00000001, pqac-00000005) | Case report + literature review | Oryani et al., *Journal of Obstetrics, Gynecology and Cancer Research* | 2024-08 | DOI: 10.30699/jogcr.9.5.591 | https://doi.org/10.30699/jogcr.9.5.591 |
| Tumor risk / management | Reported malignancy risk **37–45%** overall; dysgenetic gonads carry ~**30% risk of gonadoblastoma**; gonadoblastoma may transform to malignant germ-cell tumor in **50–60%** of cases; prophylactic gonadectomy and estrogen-based HRT recommended (pqac-00000002) | Case report + literature review | Adra et al., *Journal of Clinical Research in Pediatric Endocrinology* | 2024-04 | DOI: 10.4274/jcrpe.galenos.2023.2023-12-11 | https://doi.org/10.4274/jcrpe.galenos.2023.2023-12-11 |
| Tumor risk / management | Gonadoblastoma occurs in about **20–30%**; **>40%** of gonadoblastomas reported as bilateral; early prophylactic gonadectomy, HRT for pubertal induction/bone health, and fertility via donor oocytes/ART discussed (pqac-00000004) | Case report / review | Jawed et al., *Women’s Health* | 2023-01 | DOI: 10.1177/17455057231213270 | https://doi.org/10.1177/17455057231213270 |
| Familial tumor risk / genetics | In reviewed familial cases, **27/30** underwent gonadectomy and **18/27 (66.6%)** had gonadal tumors; tumors reported only in patients >10 years; familial heterogeneity includes **MAP3K1, DHH, SRY, NR5A1, DAX1**-related findings (pqac-00000006) | Case report + literature review | Rudnicka et al., *Journal of Clinical Medicine* | 2024-01 | DOI: 10.3390/jcm13030785 | https://doi.org/10.3390/jcm13030785 |
| Diagnostics / tumor prevention | Early workup of primary amenorrhea and absent puberty should include imaging, karyotype/cytogenetics, hormone testing, and histology when needed; prophylactic gonadectomy can prevent dysgenetic-gonad tumors; DSD prevalence broadly cited as ~**1:1000 births** in review context (pqac-00000003, pqac-00000007) | Case report / review | Sowińska-Przepiera et al., *International Journal of Environmental Research and Public Health* | 2023-01 | DOI: 10.3390/ijerph20032139 | https://doi.org/10.3390/ijerph20032139 |
| Genetics / molecular diagnosis | Early genomic testing recommended; **up to 2/3** of 46,XY DSD may remain without molecular diagnosis; gene evidence table includes **NR5A1** (high evidence) among 46,XY gonadal dysgenesis genes; stepwise testing: chromosomal sex confirmation, rapid Y/SRY tests, microarray/CNV analysis, targeted panels, then WES (pqac-00000008, pqac-00000010, pqac-00000012, pqac-00000013, pqac-00000014) | Clinical review | O’Connell et al., *Hormone Research in Paediatrics* | 2023-11 | DOI: 10.1159/000520926 | https://doi.org/10.1159/000520926 |
| Diagnostics / yield | DSD gene panels reported diagnostic yields of **20–45%**; WES useful for unsolved cases and novel/oligogenic causes but may miss noncoding/CNV changes; a UK cohort cited **52%** of genetically confirmed 46,XY DSD had apparently normal hormone profiles, supporting genomic testing beyond endocrine screening (pqac-00000009, pqac-00000010) | Clinical review | O’Connell et al., *Hormone Research in Paediatrics* | 2023-11 | DOI: 10.1159/000520926 | https://doi.org/10.1159/000520926 |
| Genetics / worldwide diagnostic landscape | Approximately **50%** of 46,XY DSD patients lack a molecular diagnosis; most commonly mutated gonadal-development genes are **NR5A1** and **MAP3K1**; review states **WES** generally gives higher diagnostic yield than panel sequencing, although cohort performance varies by ascertainment and method (pqac-00000016) | Worldwide cohort review | Chen Jiali et al., *Frontiers in Genetics* | 2024-06 | DOI: 10.3389/fgene.2024.1387598 | https://doi.org/10.3389/fgene.2024.1387598 |
| Genetics / diagnostic yield statistics | Across cohorts, molecular diagnostic rates ranged **24.3%–64.3%**; one summary reported **43%** of 46,XY DSD receiving a possible genetic diagnosis; common genes include **AR, SRD5A2, NR5A1**, with **MAP3K1** also recurrent in some cohorts (pqac-00000017, pqac-00000018, pqac-00000019) | Worldwide cohort review | Chen Jiali et al., *Frontiers in Genetics* | 2024-06 | DOI: 10.3389/fgene.2024.1387598 | https://doi.org/10.3389/fgene.2024.1387598 |
| Genetics / mechanism / counseling | **NR5A1** variants show broad phenotypic range including complete gonadal dysgenesis; lack of clear genotype-phenotype correlation; possible oligogenic contribution; early genetic testing and fertility counseling/preservation are advised (pqac-00000020, pqac-00000021) | Gene-focused review | Luppino et al., *Current Issues in Molecular Biology* | 2024-05 | DOI: 10.3390/cimb46050274 | https://doi.org/10.3390/cimb46050274 |
| Diagnostic workflow figure | Figure 1 presents a practical stepwise diagnostic/genetic workflow for DSD: clinical suspicion → rapid Y/SRY detection (esp. neonates) → baseline hormones → microarray/CNV assessment → targeted testing or exome-based DSD analysis (pqac-00000028) | Figure / workflow from review | O’Connell et al., *Hormone Research in Paediatrics* | 2023-11 | DOI: 10.1159/000520926 | https://doi.org/10.1159/000520926 |


*Table: This table summarizes key 2023-2024 sources for 46,XY complete gonadal dysgenesis/Swyer syndrome across phenotype, genetics, tumor risk, diagnostics, and management. It highlights the most actionable statistics and recent diagnostic-yield statements for rapid evidence review.*